Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Smith & Nephew plc (SNN) Price & Performance

YieldMax NVDA Option Income Strategy ETFTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

YieldMax NVDA Option Income Strategy ETF vs Smith & Nephew plc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $13.04, while Smith & Nephew plc trades at $29.65 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and YieldMax NVDA Option Income Strategy ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.

NVDYSNN
Sector
Income / Options OverlayHealth
52-Week High
$17.96$38.70
52-Week Low
$11.58$28.73
Market Cap
$12.54B
Enterprise Value
$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax NVDA Option Income Strategy ETF

NVDY trades at $13.00, up 2.12% on the day, with technical indicators showing a bullish trend but overbought conditions on short-term RSI. The ETF generates income through weekly distributions, with recent dividends ranging from $0.09 to $0.15 per share. News highlights focus on its strategy of selling NVIDIA call options to fund payouts, sacrificing some upside for yield.

The outlook hinges on NVIDIA's volatility sustaining option premiums, offering high income but capping gains. Risks include underperformance vs. NVIDIA stock and fee drag. Analyst sentiment is mixed, weighing income benefits against opportunity costs, with institutional interest driven by yield-seeking investors.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.

Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.

Returns comparison

Trailing returns across standard periods

About YieldMax NVDA Option Income Strategy ETF

NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.

Read more on NVDY

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN